ARTICLE | Clinical News
AS1411: Phase I data
May 23, 2005 7:00 AM UTC
Data from a Phase I trial in 17 patients showed that AS1411 was safe and well tolerated. Also, 7 patients showed stable disease for 2 months or more and 1 patient had a near complete response. ASM pla...